Clinical trials are a critical part of the development of new treatments. They rely on people who volunteer to participate and are then closely monitored by...
Considering Whether Criteria for Clinical Trials Exclude Too Many Patients
read more
Advocacy & Policy
Announcing New 2018 Grants
As our programs at TargetCancer Foundation continue to expand, we remain committed to our primary mission of funding innovative rare cancer research. We are...
Right to Try, Access, and Safety.
Earlier this week, TargetCancer Foundation joined with the National Organization of Rare Disorders (NORD) and 81 other rare advocacy organizations to express...
Eight Years of Impact on Rare Cancer
The following post is written by Kristen Palma Poth, TargetCancer Foundation President Eight. It is a number that carries a meaning for me that I never could...
Rare Disease Week on Capitol Hill 2017
Citizen Advocacy – DC legislators welcome our passionate voices during Rare Disease Week 2017 by Bill Drake, TargetCancer Foundation Advocacy Council Member...
Washington DC Recap: ACA Repeal and Its Impact on Cancer Patients
By TargetCancer Foundation Advocacy Council Member DJ Webster Last Thursday, TargetCancer Foundation traveled to Washington D.C. for the annual in-person...